Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $425
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $410 to $425.
August 04, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $410 to $425, which could potentially drive the stock price up.
The raised price target by Wells Fargo indicates a positive outlook for Vertex Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100